• Vaccine Name: LV20/DP
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The vaccine antigen is a fusion protein (L20) composed of HBHA and MTP from Mycobacterium tuberculosis, which are displayed on virus-like particles (Wang et al., 2023).
• HBHA gene engineering:
  • Type: Fusion Protein
  • Description: This is use for fusion protein preparation(Wang et al., 2023).
  • Detailed Gene Information: Click Here.
• MTP gene engineering:
  • Type: Fusion Protein
  • Description: Use in preparation of fusion protein(Wang et al., 2023).
  • Detailed Gene Information: Click Here.
• Preparation: The vaccine was prepared using a baculovirus–insect cell (Sf9) expression system and purify virus-like particles by using sucrose gradient ultracentrifugation (Wang et al., 2023).
• Immunization Route: subcutaneous injection
• Storage: The purified virus-like particles were stored at −80 °C prior to use.(Wang et al., 2023)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Mice were immunized subcutaneously with LV20, HBHA/DP, or LV20/DP on days 0, 28, and 84, while BCG and PBS were administered as single-dose controls (Wang et al., 2023).
• Persistence: Vaccine-induced immune responses persisted for several weeks after the final immunization, as antigen-specific T cell responses and antibody levels were detected up to 42–84 days post-immunization (Wang et al., 2023).
• Immune Response: Vaccination with LV20 formulated with DDA and Poly I:C elicited strong HBHA-specific CD4? and CD8? T cell responses, with increased production of IFN-? and IL-2, as well as elevated levels of HBHA-specific IgG, IgG1, and IgG2c antibodies(Wang et al., 2023).
• Challenge Protocol: Immunized mice were challenged intranasally with 5 × 10⁶ CFU of Mycobacterium tuberculosis H37Ra, and lung bacterial loads were measured 21 days post-challenge(Wang et al., 2023).
• Efficacy: Vaccination with LV20 formulated with DDA and Poly I:C significantly reduced lung bacterial burden by approximately 1.2–1.3 log₁₀ CFU compared to control groups (Wang et al., 2023).
• Information about this animal model: Mouse Model for TB research